Results 11 to 20 of about 14,298 (222)

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Journal of Immunology Research, 2017
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on ...
Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, Stéphane Birklé   +7 more
doaj   +2 more sources

Biology of GD2 ganglioside: implications for cancer immunotherapy [PDF]

Frontiers in Pharmacology, 2023
Part of the broader glycosphingolipid family, gangliosides are composed of a ceramide bound to a sialic acid-containing glycan chain, and locate at the plasma membrane.
Pierre Machy, Erwan Mortier, Stéphane Birklé   +2 more
doaj   +2 more sources

GD2 expression in breast cancer [PDF]

Oncotarget, 2017
Breast cancer (BC) is a heterogeneous disease, including different subtypes having diverse incidence, drug-sensitivity and survival rates. In particular, claudin-low and basal-like BC have mesenchymal features with a dismal prognosis. Disialoganglioside GD2 is a typical neuroectodermal antigen expressed in a variety of cancers.
ORSI, GIULIA, BARBOLINI, MONICA, Ficarra, G, TAZZIOLI, Giovanni, MANNI, Paola, PETRACHI, TIZIANA, MASTROLIA, ILENIA, Orvieto, E, SPANO, Maria Carlotta, PRAPA, MALVINA, KALECI, SHANIKO, D'AMICO, Roberto, Guarneri, V, Dieci, Mv, CASCINU, Stefano, Conte, P, PIACENTINI, Federico, DOMINICI, Massimo   +17 more
openaire   +5 more sources

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. [PDF]

PLoS ONE, 2014
Anti-GD2 antibody is a proven therapy for GD2-positive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies.
Mickaël Terme, Mylène Dorvillius, Denis Cochonneau, Tanguy Chaumette, Wenhua Xiao, Mitchell B Diccianni, Jacques Barbet, Alice L Yu, François Paris, Linda S Sorkin, Stéphane Birklé   +10 more
doaj   +4 more sources

GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma [PDF]

Clinical Cancer Research
Abstract Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects ...
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, Michele Pezzella, Simona Caruso, Simona Manni, Alessio Ottaviani, Marika Guercio, Francesca Del Bufalo, Maria Cecilia Quadraccia, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Mariasole Aurigemma, Laura Iaffaldano, Andrea Sarcinelli, Maria Luisa D'Amore, Manuela Ceccarelli, Francesca Nazio, Veronica Marabitti, Ezio Giorda, Marco Pezzullo, Cristiano De Stefanis, Andrea Carai, Sabrina Rossi, Rita Alaggio, Giada Del Baldo, Marco Becilli, Angela Mastronuzzi, Biagio De Angelis, Franco Locatelli   +30 more
openaire   +8 more sources

DNA Vaccine Expressing the Mimotope of GD2 Ganglioside Induces Protective GD2 Cross-reactive Antibody Responses

Cancer Research, 2005
AbstractThe GD2 ganglioside expressed on neuroectodermally derived tumors, including neuroblastoma and melanoma, is weakly immunogenic in tumor-bearing patients and induces predominantly immunoglobulin (Ig)-M antibody responses in the immunized host. Here, we investigated whether interconversion of GD2 into a peptide mimetic form would induce GD2 cross-
Bolesta, Elizabeth, Kowalczyk, Aleksandra, Wierzbicki, Andrzej, Rotkiewicz, Piotr, Bambach, Barbara, Tsao, Chun-Yen, Horwacik, Irena, Kolinski, Andrzej, Rokita, Hanna, Brecher, Martin, Wang, Xinhui, Ferrone, Soldano, Kozbor, Danuta   +12 more
openaire   +4 more sources

Expression of GD2 and GD3 in peripheral neuroblastic tumors

Indian Journal of Pathology and Microbiology
Purpose: The aim of this study was to explore the correlation between the expression of GD2 and GD3 and the histopathological types, risk groups, and chemotherapy in peripheral neuroblastic tumors (pNTs) and provide a theoretical basis for the selection ...
Xia Wei, Shaomei Li, Yizhen Wang
doaj   +2 more sources

Frequency of ALK and GD2 Expression in Neuroblastoma

Fetal and Pediatric Pathology, 2019
Background: The aim of this study was to elucidate the significance of immunohistochemical staining patterns of ALK and GD2 in peripheral neuroblastic tumors with different stages and favorable/unfavorable features. Materials and methods: 32 neuroblastomas, 7 ganglioneuroblastomas, and 1 ganglioneuroma cases were immunohistochemically stained with ALK ...
Aygün, Zeynep, Batur, Şebnem, Emre, Şenol, Celkan, Tiraje, Ozman, Oktay, Comunoglu, Nil   +5 more
openaire   +3 more sources

Intermediary filament and GD2-expression in astrocytic tumors

, 2008
By means of immunhistochemical markers the expression of glial fibrillary acidic protein, vimentin and glykosphingolipid GD2 is investigated in 28 astrocytic tumors grading WHO II-IV. Statistically, there is found a high correlation in the cytoplasmatic expression of GFAP/GD2 as well as Vimentin/GD2 and GFAP/Vimentin.The semiquantitatively strongest ...
Lell, Barbara, Mennel, H.D. (Prof. Dr.)
core   +4 more sources

A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics

Molecular Therapy: Nucleic Acids, 2021
Because current mainstream anti-glycolipid GD2 therapeutics for neuroblastoma (NB) have limitations, such as severe adverse effects, improved therapeutics are needed. In this study, we developed a GD2 aptamer (DB99) and constructed a GD2-aptamer-mediated
Liyu Zhang, Meng Wang, Zeen Zhu, Shengquan Chen, Haibin Wu, Ying Yang, Fengyu Che, Qiao Li, Hui Li   +8 more
doaj   +1 more source